These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 10382871

  • 21. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H, Kusano N.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.
    Tankovic J, Mahjoubi F, Courvalin P, Duval J, Leclerco R.
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2558-61. PubMed ID: 8913464
    [Abstract] [Full Text] [Related]

  • 27. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 28. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [Abstract] [Full Text] [Related]

  • 29. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
    Schmitz FJ, Fluit AC, Lückefahr M, Engler B, Hofmann B, Verhoef J, Heinz HP, Hadding U, Jones ME.
    J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
    [Abstract] [Full Text] [Related]

  • 30. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [Abstract] [Full Text] [Related]

  • 31. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli.
    Conrad S, Oethinger M, Kaifel K, Klotz G, Marre R, Kern WV.
    J Antimicrob Chemother; 1996 Sep; 38(3):443-55. PubMed ID: 8889719
    [Abstract] [Full Text] [Related]

  • 32. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
    Dessus-Babus S, Bébéar CM, Charron A, Bébéar C, de Barbeyrac B.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2474-81. PubMed ID: 9756744
    [Abstract] [Full Text] [Related]

  • 33. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
    Chen JY, Siu LK, Chen YH, Lu PL, Ho M, Peng CF.
    Microb Drug Resist; 2001 Oct; 7(1):47-53. PubMed ID: 11310803
    [Abstract] [Full Text] [Related]

  • 34. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
    Ruiz J, Marco F, Sierra JM, Aguilar L, Garcia-Mendez E, Mensa J, Jiménez De Anta MT, Vila J.
    Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
    [Abstract] [Full Text] [Related]

  • 35. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Köhrer K, Schmitz FJ.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [Abstract] [Full Text] [Related]

  • 36. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ.
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [Abstract] [Full Text] [Related]

  • 37. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
    Zhanel GG, Karlowsky JA, Hoban DJ.
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
    [Abstract] [Full Text] [Related]

  • 38. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.
    Weigel LM, Steward CD, Tenover FC.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2661-7. PubMed ID: 9756773
    [Abstract] [Full Text] [Related]

  • 39. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
    Varon E, Janoir C, Kitzis MD, Gutmann L.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
    [Abstract] [Full Text] [Related]

  • 40. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
    Bébéar CM, Renaudin H, Charron A, Bové JM, Bébéar C, Renaudin J.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2304-11. PubMed ID: 9736554
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.